MINI FUTURE LONG - BAVARIAN NORDIC | Real-time Bid/Ask 07:54:03 2024-07-01 EDT | ||
| 0.75 EUR / 0.76 EUR | -0.66% |
|
| Current month | -16.48% | ||
| 1 month | -11.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BAVARIAN NORDIC A/S
Latest news about BAVARIAN NORDIC A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 0.77 | +1.32% |
| 24-06-28 | 0.76 | -21.65% |
| 24-06-27 | 0.97 | +4.30% |
| 24-06-26 | 0.93 | +78.85% |
| 24-06-25 | 0.52 | -7.14% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 03:48 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BAVARIAN NORDIC A/S |
| Issuer | Morgan Stanley |
| WKN | MG2J4J |
| ISIN | DE000MG2J4J8 |
| Date issued | 2024-04-17 |
| Strike | 116.1 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.97 € |
|---|---|
| Lowest since issue | 0.41 € |
| Spread | 0.01 € |
| Spread % | 1.32% |
Company Profile
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%).
Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).
Sector
-
Consensus: Bavarian Nordic A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
172.6
DKK
Average target price
263.2
DKK
Spread / Average Target
+52.49%
- Stock Market
- Certificates
- Certificat
